Retatrutide 40 mg Peptide Pen

What Is the Retatrutide 40 mg Peptide Pen?

The Retatrutide 40 mg Peptide Pen contains a prepared solution in a prefilled, multiple-dose format, with 40 mg total labeled content per pen. Each kit includes eight disposable 32G × 4 mm needles and a printed user guide. A Certificate of Analysis (COA) is available separately.

Retatrutide, also known as LY3437943, is an investigational peptide studied for weight management and metabolic regulation. It acts on three hormone receptors—GLP-1, GIP and glucagon—involved in appetite, glucose regulation and energy metabolism. Published clinical findings concern the study medication and do not establish the effectiveness of this particular pen.

What Comes in the Box?

• One Retatrutide 40 mg prefilled pen.
• Eight individually packaged disposable needles measuring 32G × 4 mm.
• One printed user guide.

The eight included needles describe the accessory count. They do not establish the number of doses or a treatment schedule.

Product Specifications

• Product format: Prefilled, multiple-dose peptide pen.
• Compound: Retatrutide.
• Alternative identifier: LY3437943.
• Total labeled content: 40 mg per pen.
• Presentation: Prepared solution.
• Quantity: One pen per retail pack.
• Included accessories: Eight disposable needles and a printed user guide.
• Needle dimensions: 32G × 4 mm.
• Brand shown on packaging: Tera.

Certificate of Analysis

The Certificate of Analysis is available below for review. Refer to the report for the sample identifier, laboratory, test methods and reported results.

View Certificate of Analysis (PDF)

What Is Retatrutide?

Retatrutide is a peptide investigated for its effects on body weight and metabolic regulation. It is also identified in scientific literature as LY3437943. Researchers describe it as a triple receptor agonist because it acts at GLP-1, GIP and glucagon receptors.

These receptor systems participate in the regulation of appetite, glucose handling and energy metabolism. Retatrutide brings activity at all three into a single molecule, making its combined receptor profile a central subject of clinical research.

How Does Its Three-Receptor Activity Work?

GLP-1: Appetite and Glucose Regulation

GLP-1 receptor signaling contributes to appetite regulation and supports insulin release in response to elevated blood glucose.

GIP: The Insulin Response to Nutrients

GIP is involved in the body’s hormonal response to food. Its receptor activity supports glucose-dependent insulin secretion and is studied alongside GLP-1 activity in metabolic treatments.

Glucagon: Energy and Glucose Metabolism

Glucagon receptor signaling influences liver glucose production and energy metabolism. Researchers are examining how this activity interacts with the GLP-1 and GIP components of retatrutide’s receptor profile.

What Has Research Shown About Weight Management?

A randomized phase 2 trial published in the New England Journal of Medicine examined retatrutide in adults with obesity or overweight and a weight-related condition. At 48 weeks, the highest-dose study group had an estimated average body-weight reduction of 24.2%, compared with 2.1% in the placebo group.

These findings relate to the investigational medication and conditions used in that clinical trial. They do not demonstrate the effectiveness, composition or expected results of this commercially supplied pen.

Read the published phase 2 retatrutide study.

How Does This Pen Presentation Differ From a Powder Vial?

The packaging describes this product as a prefilled pen containing a solution. Many other retatrutide listings describe lyophilized powder supplied in vials. This distinction matters when comparing product format, package contents and accompanying documentation.

This kit includes a pen with a protective cap, an indicator window and an end dial, together with eight disposable needles and a printed guide. These are differences in presentation and accessories; they do not establish greater effectiveness, purity or safety than another product.

Ingredients Shown on the Carton

In addition to retatrutide, the packaging lists sodium chloride, sodium dihydrogen phosphate heptahydrate, sodium hydroxide, dilute hydrochloric acid and water for injections.

Check the labeling supplied with the product for batch-specific information. Storage conditions and expiry should be taken from verified product documentation rather than assumed from another peptide product.

Research and Safety Information

Retatrutide remains investigational. The published phase 2 trial reported gastrointestinal adverse effects and dose-dependent increases in heart rate. Clinical findings should be considered alongside the limitations and safety information in the original research.

The 40 mg figure is the total labeled content of the pen. It is not an individual dose recommendation. Neither the package quantity nor the number of needles establishes a suitable treatment schedule.

Frequently Asked Questions

Is this a pen or a vial?

This listing is for a prefilled peptide pen. The photographs show the pen, its retail packaging and the included accessories.

Does each pen contain 40 mg in total?

Yes. The packaging identifies 40 mg as the total retatrutide content per pen.

Are needles included?

Yes. Each box includes eight individually packaged disposable needles measuring 32G × 4 mm, along with a printed user guide.

Where can I find the laboratory report?

Use the Certificate of Analysis link above to open the available PDF. Review the report itself for the sample details and the scope of testing.

Does a prefilled format mean better results?

No conclusion about effectiveness can be drawn from the delivery format alone. The prefilled presentation describes how the product is supplied.